In contrast, depleting CD19+ B cells or blocking OPRL1 led to increased tumor growth, reduced CD8+ T-cell infiltration and cytotoxic potential, exacerbated pain, and elevated CGRP levels. Here, OPRL1 is linked to neoplasm.